One important case report described a patient with refractory GRE due to an IDH1mut oligodendroglioma in which the IDH1 inhibitor ivosidenib was effective in reducing the patient’s seizure frequency (Vo et al., 2022). Here, IDH1 is linked to oligodendroglioma.